|
Post by dayanand33 on Jan 7, 2015 21:18:43 GMT
Yelk, I don't own any CUR shares but will keep an eye on this one for an entry point in the coming weeks. I certainly expect a run up towards release of the topline P2 results. Also, I just saw this blog by a trial patient that I want to share. It is a good read to learn about the life of someone suffering from this horrible disease and the hope that this clinical trial provides; aprilals.com/I have been watching this stock for a few months. For the past few days the volume has been > 3 times the average volume and the stock has been on a steady rise. I think it is not too late to get in. CEO is scheduled to present on the 13th Jan. www.prnewswire.com/news-releases/neuralstem-to-present-at-biotech-showcase-2015-300016195.html The top line results for phase 2a (ALS) is scheduled sometime in first quarter. It is sure to generate a lot of interest and the pps is unlikely to crash from here until the results are known.
|
|
|
Post by dayanand33 on Jan 7, 2015 21:20:59 GMT
Since these are Chinese trials, market may have some reservations betting on it. What's driving up the pps is the anticipation of phase 2a conducted in US under the supervision of FDA.
|
|
|
Post by Yelk on Jan 8, 2015 2:23:19 GMT
Got my feet wet in this one today - testing the waters up 3%. About half of my ATHX position which is already a small one. I have a bad gut feeling about CUR and I don't know why. Probably just skepticism over the PPS steady rise the last while. I seem to be making a pattern of buying in a month too late for partial gains, trying to break that habit.
|
|
|
Post by mycargoesfast on Jan 8, 2015 2:50:18 GMT
Got my feet wet in this one today - testing the waters up 3%. About half of my ATHX position which is already a small one. I have a bad gut feeling about CUR and I don't know why. Probably just skepticism over the PPS steady rise the last while. I seem to be making a pattern of buying in a month too late for partial gains, trying to break that habit. I've been with them a long time, but I had a similar feeling about the rise and put in a stop order in this afternoon. I don't feel like following them down again.
|
|
|
Post by Yelk on Jan 15, 2015 4:13:14 GMT
Waiting for the entry point for this for the run up to March 1. Going to be hard to time it, if it goes under 3 I'll start adding if not small before. About 6 weeks to go. 200 day MA is 3.4. Right now it is a nice position as it fell 14-15% in the last several days due to delay in data release and last pull outs.
|
|
|
Post by mycargoesfast on Jan 23, 2015 15:01:36 GMT
I finally had some time to listen to the Neuralstem BioTech showcase presentation from 1/13/2015 (see link below). Sounds like they are planning to monitize the stroke treatement in China where they are holding the trials and don't have any immediate plans to bring it to the US. I still like this company they are doing great things, stock seems to be stabilizing around $3.00. I'm currently on the sideline, but I do see this stock hitting new highs this year, when? I don't know. investor.neuralstem.com/index.php?s=126&item=166
|
|
|
Post by Yelk on Jan 28, 2015 3:44:16 GMT
I also listened to the presentation and doubled my tiny position on Monday. Now we wait and see what kind of run up there will be. I'm anticipating a TP of $3.60 to $4 for the run up as more people became aware of it, especially pumpers from the prior run up so we have a lot more people involved. However that is just speculation - either way I am 99% sure this won't go below $3.12 and should be considered "lower" risk as of today. But always remember - in this world, especially in investing nothing is certain.
|
|
|
Post by mycargoesfast on Jan 28, 2015 22:16:56 GMT
I concur that its going up, probably sooner than later. I looked over the showcase slides again, report out on ALS phase 2 data within next few months (Q1/Q2). Data they provided in the slides looks fantastic. Definately the type of treatment that could get fast track breakthrough designation from FDA. I'm no chart guy but I'll probably pick it back up tomorrow I could see this going up to the 52 week high of $4.60 if they play their cards right and meet their targets (and they usually do).
|
|
|
Post by Yelk on Jan 31, 2015 2:46:31 GMT
Upped my position here on the downward trend. Any more interest on CUR from this forum? I'm curious how BCLI will be affected if CUR's results are positive. I was a bit confused by 2 seeking alpha articles by Zacks one said thought CUR would be positive results like BCLI but BCLI > CUR. Still think I may reduce BCLI stock just in case before the release. Then again if results are bad maybe BCLI wil go up? Lol.
|
|
|
Post by Yelk on Feb 1, 2015 17:41:54 GMT
thealsexpress.com/facing/ A post written by one of the patients who is 14 months after surgery and 3 years+ after ALS diagnose. Looks quite promising - but of course over all results can be totally different. seekingalpha.com/article/2797975-15-biotech-names-for-2015 Also a good read on outlook for CUR. GLTA. Still a bit in the shade when results come out for this one. The patient said about today but that was before CUR made the announcement I believe that it would be postponed until March/April. www.kregpalkoals.com/family-journal another blog from CUR patient as recent as a few days ago.
|
|
|
Post by Yelk on Feb 4, 2015 4:34:52 GMT
Wow, post market trading 16:11 a block for almost .4 million shares... is that a buy or sell. Unless my eyes are deceiving me.
|
|
|
Post by lcd on Feb 5, 2015 15:36:23 GMT
I couldn't get shares of NRIFF at the price I wanted this week so I gave up on them and bought a small block of CUR for just over $3. I will add to it if it dips below $3. Otherwise, I will just ride this small holding through the P2 results. I might also double down on my BCLI holdings in anticipation of them getting a bump from CUR's results.
|
|
|
Post by Yelk on Feb 5, 2015 15:45:38 GMT
I completely sold out of BCLI today as CUR shows this is a consolidation range for future run-up. I've done a lot of DD recently and read the blogs of several CUR patients. I have no idea what price we could hit on positive results but I am feeling 60-70% confident which is surprising I'm usually very pessimistic . On the flip side if CUR fails BCLI made see a medium level boost?
|
|
|
Post by lcd on Feb 5, 2015 15:58:20 GMT
Yelk, CUR definitely has the near term catalyst but I feel BCLI is undervalued with their tiny market cap so I like them for the long play. I think BCLI will go up or down with CUR's results so I hope a rising tide floats all boats.
|
|
|
Post by Yelk on Feb 6, 2015 4:16:56 GMT
100% Agree just short on cash right now don't have any room for longs... I'll probably get back in tomorrow before the week of conferences. I am pretty confident in positive results from CUR though and I don't see BCLI going up if CUR is successful unless I need to do more DD and its the other way around? Competition vs information.
|
|
|
Post by lcd on Feb 6, 2015 15:41:28 GMT
CUR went from about $2.60 to $3.60 during the brief BCLI run then also quickly faded back to $3 last month. Unless CUR has patients doing cartwheels at the data release, I think it is too early to pick a winner and loser in these competitors. Hopefully, they will both be winners.
|
|
|
Post by Yelk on Feb 6, 2015 15:47:05 GMT
This run could have been due to the fact that CUR had a better chance of showing efficacy. Would make perfect sense why CUR would go up. If CUR shows efficacy it doesn't change much about perspective on BCLI because BCLI has already proven itself. However in these particular companies I don't see CUR's positive results negatively affecting BCLI. I think people are willing to take anything they can get for ALS and as you mentioned it is too early to tell or care from a competitive standpoint at this time.
|
|
|
Post by dayanand33 on Feb 7, 2015 14:02:04 GMT
|
|
|
Post by Yelk on Feb 8, 2015 23:36:16 GMT
Some notes as we continue towards spring. Thanks dayanand33 for the above. www.youtube.com/watch?v=v5rcBLjck68 A one hour video with Dr. Eva on ALS that included some detailed comments on the phase the NSI-566 stem cells. She has been very positive on the phase 1 results. She has made essential the same comments as Dr. Glass on the phase 1 results stating that patients 10, 11 and 12 have shown stabilized disease at three years post diagnosis. She has indicated that the phase 2 trial has also produced encouraging results, but has not provided details. Enrollment in this trial was completed in July 2014 and the study should complete in early 2015. No interim results have been released to date, but Dr. Feldman has said “I wouldn’t be spending all my waking hours on writing the next phase trial, if I do not believe in the phase II data.” I would anticipate that she will present data on interim results at the American Neurological Association Annual Meeting in Baltimore from October 12 through 14. We have to keep in mind the following: -Obviously investors pay attention to ALS as seen by BCLI jump. -This trial is a much larger trial and not based only in Israel. This will not only raise it higher but maintain more strength and credibility. -There are multiple blogs by CUR patients that I've read thoroughly that think this really helped and their comments are: "We were so happy to be able to be in the P2 and hope for all the best for P3 patients - thank you P1 for taking this risk, we don't deserve this as friends we speak with can't get out of bed and we complain because we can't drive." Lots of consolidation in the $3.07 range. Don't let this stock fool you IMO. I wouldn't be at all surprised if it dropped below $3 before the run-up. I have a feeling when it happens, IF it happens we could see a profound run-up. I will be perfectly happy adding all the way down to $2.40. Not really anticipating the run up until maybe mid March at earliest anyways. The only reason I have a decent position now is because with all stocks everything is 100% unpredictable. We could see a slow incline over the next month and it would be a shame to miss that. My plan will be to add in small increments as we go down (if we go down). As Jason Napadano said: "There may be no larger catalyst in our coverage universe for 2015." The CEO said: "We may be commercialization as early as 2 years." She wrapped up with: "Phase II data was complete January 1. On February 1, I broke the data. I wanted to share it with you. It will be available, I hope, in April. I'm sorry I can't share it with you. I was asked by the Company and FDA not to share." "Invite me back in a few months." She mentioned the whole thing was "very exciting" and she has go-ahead for Phase III. Not to be pumpy or anything and I caution everyone to be vigilant for actual result - but all of the above is valid reasons for considering the run-up and holding a small amount through press release. Also CEO said end of Q1 early in Q2 and Eva said April. This could mean even the by the last couple days of March so keep an eye out.
|
|
|
Post by dayanand33 on Feb 9, 2015 20:57:33 GMT
Just got off from the presentation call. My gut feel was correct. TLD release is scheduled late feb or early march. I transferred some of athx funds into CUR. I am highly bullish about this stock leading to TLD results.
|
|